Exploring the Mechanism of Epimedium brevicornu Maxim.for Treating Rheumatoid Arthritis Based on Network Pharmacology and Molecular Docking
To gain a deeper understanding of the mechanism by which Epimedium brevicornu Maxim.treats rheumatoid arthritis(RA),network pharmacology and molecular docking techniques for analysis were employed.The intersection target proteins of E.brevicornu Maxim.and RA through databases and related software were obtained,the protein-protein interaction(PPI)network and ″medicinal material-component-target″ interaction network were constructed,the target proteins were enriched and analyzed,and protein molecule docking was performed.The results indicated that the core target proteins of E.brevicornu Maxim.for treating RA might be TNF,AKT1,TP53,ALB,SRC,etc.The active ingredients might be β-sitosterol,8-isopentenyl kaempferol,sitosterol,kaempferol,luteolin,quercetin,etc.The signal pathway might be the signal pathway in cancer,lipid,and atherosclerosis.The molecular docking showed that the active ingredients of E.brevicornu Maxim.for treating RA had excellent binding activity with target proteins.The results demonstrated that E.brevicornu Maxim.,in the treatment of RA,possessed characteristics of multiple components,multiple targets,and multiple pathways,providing a solid theoretical foundation for its experimental research and clinical treatment.
国家科技期刊平台
NSTL
万方数据
